样式: 排序: IF: - GO 导出 标记为已读
-
Update on T-Cell Lymphoma Epidemiology Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-03-07 Jane J. Chen, Franco Castillo Tokumori, Christina Del Guzzo, Jeanyoung Kim, Jia Ruan
Purpose of Review T-cell lymphomas (TCLs) are a group of rare subtypes of non-Hodgkin lymphoma derived from mature T-lymphocytes. Recent updates in lymphoma classification based on the cell-of-origin pathogenesis have shed new light on TCL epidemiology and outcomes. Contemporary regional consortia and international studies, including those conducted recently in Asia and South America, have provided
-
Management of Patients with Early Myelofibrosis: A Discussion of Best Practices Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-03-05 Prithviraj Bose
-
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-02-23 Delphine Rea, Sofiane Fodil, Etienne Lengline, Emmanuel Raffoux, Jean-Michel Cayuela
Purpose of Review The discovery that patients suffering from chronic myeloid leukemia who obtain deep and long-lasting molecular responses upon treatment with tyrosine kinase inhibitors may maintain their disease silent for many years after therapy discontinuation launched the era of treatment-free remission as a key management goal in clinical practice. The purpose of this review on treatment-free
-
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-02-19 Fatima Warsame, Douglas A. Simonetto
-
Frontline Therapy of CLL—Changing Treatment Paradigms Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-02-10
Abstract Purpose of Review The therapeutic landscape for chronic lymphocytic leukemia (CLL) has undergone a complete makeover following the introduction of highly effective targeted therapies, beginning with ibrutinib which first attained regulatory approval for CLL in 2014. Recent Findings In recent years, we have seen further refinement of therapeutic options with the development of newer-generation
-
Transplantation and Cellular Therapy for Older Adults—The MSK Approach Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-02-09
Abstract Purpose of Review Hematologic malignances more commonly affect older individuals and often present with advanced, higher risk disease than younger patients. Allogeneic and autologous hematopoietic cell transplantation is well-established treatment modalities with curative potential following either frontline treatments for these diseases or salvage therapy in the relapsed or refractory setting
-
Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-02-05 Kelly M. Pennington, Douglas Simonetto, Timucin Taner, Abhishek A. Mangaonkar
Purpose of the Review This study aimed to summarize evidence and provide consensus-based guidelines for management of transplantation in patients with telomere biology disorders (TBD). Specifically, this review focuses on clinical management of lung, liver, and bone marrow transplantation in TBD patients. Recent Findings TBD patients have specific unique biological vulnerabilities such as T cell immunodeficiency
-
How Do We Manage Chronic Lymphocytic Leukemia in India Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-02-01 Parathan Karunakaran, Nidhi Jain, Deepesh P. Lad
-
Treatment of Richter’s Transformation with Novel Therapies Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2024-01-09 Amneet Bajwa, Alma Habib, Adam S. Kittai
Purpose of Review This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter’s transformation (RT). Recent Findings Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents;
-
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-12-30 Kathryn T. del Valle, Eva M. Carmona
-
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-12-14 Terra Lasho, Mrinal M. Patnaik
-
Novel Biomarkers and Molecular Targets in ALL Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-12-04 Hong De Sa, Jessica Leonard
-
Blinatumomab in Practice Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-12-07 Jeffrey Lantz, Natalie Pham, Caroline Jones, Daniel Reed, Firas El Chaer, Michael Keng
Purpose of Review Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related to abnormal B cell proliferation known as B-cell ALL. The course is challenging, with less-than-optimal survival outcomes, even with aggressive multiagent chemotherapy and consideration for stem cell transplantation. Novel therapies focused on targetable pathways
-
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-11-24 Abdulrahman Alhajahjeh, Aziz Nazha
Purpose of the Review This review aims to elucidate the transformative impact and potential of machine learning (ML) in the diagnosis, prognosis, and clinical management of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It further aims to bridge the gap between current advances of ML and their practical application in these diseases. Recent Findings Recent advances in ML have revolutionized
-
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-11-10 Alejandro Ferrer, Zachary D. Stephens, Jean-Pierre A. Kocher
-
Measurable Residual Disease Monitoring in Lymphoma Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-11-06 Brian Cuzzo, Andrew Lipsky, Hua-Jay J. Cherng
-
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-10-23 Naoki Oishi, Reham Ahmed, Andrew L. Feldman
-
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-10-03 Laura Ongie, Hannah A. Raj, Katie Barrett Stevens
Purpose of Review Telomere biology disorders (TBDs) encompass a spectrum of genetic diseases with a common pathogenesis of defects in telomerase function and telomere maintenance causing extremely short telomere lengths. Here, we review the current literature surrounding genetic testing strategies, cascade testing, reproductive implications, and the role of genetic counseling. Recent Findings The understanding
-
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-09-26 Stephanie L. Fetzko, Leander D. Timothy, Robin Parihar
-
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-08-31 Nicholas J. Short, Jayastu Senapati, Elias Jabbour
-
Central Nervous System Relapse in T and NK cell Lymphomas Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-08-25 Eleanor P. Taranto, Stefan K. Barta, Rahul S. Bhansali
Purpose of Review T and NK cell lymphomas are relatively rare and heterogeneous forms of non-Hodgkin lymphoma that are associated with high rates of mortality. Central nervous system relapse carries significant morbidity, though management is largely extrapolated from literature in B cell neoplasms. As such, outcomes for central nervous system involvement in T/NK cell lymphomas are dismal with no standard
-
EBV Reactivation and Lymphomagenesis: More Questions than Answers Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-08-11 Maegan Ford, Evelyn Orlando, Jennifer Effie Amengual
-
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-07-25 Megan Sears-Smith, Thomas G. Knight
Introduction Financial toxicity is a developing research area to quantify the financial stress experienced by patients and caregivers, as well as the mechanisms by which they manage the costs associated with treatment and the very real harms that this stress can inflict upon cancer care. Patients with blood malignancies experience increased costs associated with their diagnosis due to possible inpatient
-
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-07-25 Adam S. DuVall, Austin Wesevich, Richard A. Larson
Purpose of Review Largely, treatment advances in relapsed and/or refractory acute lymphoblastic leukemia (ALL) have been made in B cell disease leaving T cell ALL reliant upon high-intensity chemotherapy. Recent advances in the understanding of the biology of T-ALL and the improvement in immunotherapies have led to new therapeutic pathways to target and exploit. Here, we review the more promising pathways
-
Multiple Myeloma: Current Clinical Landscape and Compounding Costs Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-07-21 Kelsey Beck, Tyler Sandahl, Sikander Ailawadhi, Nandita Khera, Chelsee Jensen
-
Response-Adapted Therapy for Newly Diagnosed Multiple Myeloma Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-07-04 Winnie Z. Y. Teo, Ian Y. E. Ong, Jason W. Y. Tong, Wan Li Ong, Adeline Lin, Fangfang Song, Bee Choo Tai, Melissa Ooi, Cinnie Yentia Seokojo, Yunxin Chen, Chandramouli Nagarajan, Wee Joo Chng, Sanjay de Mel
-
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-07-03 Andrea Duminuco, Elena Torre, Giuseppe A. Palumbo, Claire Harrison
-
Real-world Management of CML: Outcomes and Treatment Patterns Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-07-03 Nicole Held, Ehab L. Atallah
Purpose of Review Chronic myeloid leukemia (CML) is a disease that previously signified a poor prognosis, but treatment options and outcomes have improved over the last several decades. Despite this, challenges remain in optimal management in clinical practice, as the characteristics in trial populations differ from patients who are treated in a real-world setting. This review describes recent updates
-
Richter Transformation of Chronic Lymphocytic Leukemia—Are We Making Progress? Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-06-09 Hadiyah Y. Audil, Samuel R. Kosydar, Daniel P. Larson, Sameer A. Parikh
-
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-06-06 Oluwatobi Odetola, Shuo Ma
-
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-06-01 Ji Yuan, Rong He, Hassan B. Alkhateeb
-
GATA2 Deficiency: Predisposition to Myeloid Malignancy and Hematopoietic Cell Transplantation Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-05-29 Roma V. Rajput, Danielle E. Arnold
-
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-05-24 Tiziano Barbui, Antonello Gavazzi, Edoardo Sciatti, Maria Chiara Finazzi, Arianna Ghirardi, Greta Carioli, Alessandra Carobbio
-
Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-05-17 Guadalupe Ferreira Gomes, Claire Harrison
-
A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-05-16 Josephine Anne Lucero, Jeffrey H. Lipton
Purpose of Review Long-term outcomes have significantly improved with treatment of chronic myeloid leukemia. With proper treatment, most patients will achieve similar survival rates compared to an age-matched population. Treatment-free remission is not attainable for over half of patients and chronic treatment carries with it unique challenges. We provide a pragmatic approach to the monitoring and
-
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-04-13 Prateek Pophali, Sudhamsh Reddy Desai, Aditi Shastri
-
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-04-05 Daniel E. Luna, Michi M. Shinohara
Purpose of Review Cutaneous T cell lymphomas (CTCLs) exhibit a wide variety of clinical features, histologic characteristics, and genetic drivers. We review novel molecular findings that inform our understanding of the pathogenesis of CTCL, with a focus on the tumor microenvironment (TME). Recent Findings There is increasing evidence challenging the model of TCM:mycosis fungoides (MF) and TEM:Sézary
-
Managing Survivorship after Hematopoietic Cell Transplantation Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-03-30 Nandita Khera
-
Approach to the Treatment of Philadelphia Chromosome-Negative B-cell ALL in Older Adults: Is Age Becoming just a Number? Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-03-06 Yuchen Liu, Vu H. Duong
Purpose of Review Despite progress in the treatment of pediatric B-cell acute lymphoblastic leukemia (ALL) and PH + ALL, fewer advancements have been for older adults with PH-negative B-cell ALL. Treatment of this population is mired by higher incidence of poor risk biologic features, increased incidence of medical comorbidities, and higher rates of treatment-related mortality (TRM). Here, we review
-
CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-02-15 Mika Matsuzaki, Alicia Annamalay, Pat Garcia-Gonzalez, Jerald Radich
-
The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-02-13 Shaun David Patterson, Mhairi Copland
-
CAR-T Cell Therapy: the Efficacy and Toxicity Balance Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-02-10 Karan L. Chohan, Elizabeth L. Siegler, Saad S. Kenderian
-
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-02-10 Ellin Berman
Purpose of Review The goal of this review is to summarize what is known about pregnancy in women with chronic myeloid leukemia (CML): there are very few guidelines regarding how to treat women who are pregnant at the time of CML diagnosis, and similarly, few guidelines regarding family planning for women already on tyrosine kinase inhibitor therapy who might want to start family planning. Recent Findings
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2023-01-27 Evan C. Chen, Hannah Johnston, Anand Ashwin Patel
-
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-11-22 Arleigh McCurdy, Alissa Visram
Purpose of Review Multiple myeloma (MM) is a hematologic malignancy of plasma cells that remains incurable with currently available therapies including proteosome inhibitors, immunomodulators, monoclonal antibodies, corticosteroids, and alkylators, in addition to autologous stem cell transplantation in patients who are eligible. Novel therapeutics are therefore required to improve patient outcomes
-
Molecular Pathogenesis of Myeloproliferative Neoplasms Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-11-07 Benjamin Rolles, Ann Mullally
-
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-10-24 Himachandana Atluri, Yoheved S. Gerstein, Courtney D. DiNardo
-
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-10-20 Emilia Scalzulli, Ida Carmosino, Maria Laura Bisegna, Maurizio Martelli, Massimo Breccia
Purpose of Review The clinical scenario for chronic myeloid leukemia patients rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs). Second-generation TKIs as frontline treatment increased the rate of deep molecular responses without increasing the rate of overall survival. About 20% of patients experience resistance to these agents, needing alternative treatments. Here, we reviewed
-
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-10-19 John Joson Ng, S. Tiong Ong
-
Circulating Tumor DNA in Lymphoma Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-10-10 Swetha Kambhampati, Jasmine Zain
Purpose of Review Recent advances have been made in circulating tumor DNA (ctDNA), the method to minimally invasive detect lymphoma sensitively with tumor-derived DNA in the blood of patients with lymphomas. This article discusses these various methods of ctDNA detection and the clinical context in which they have been applied to for a variety of lymphoma subtypes. Recent Findings ctDNA has been applied
-
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-10-04 Neel S. Bhatt
Purpose of Review Employment is an important indicator of health and functional recovery for hematopoietic cell transplantation (HCT) survivors and has significant social and economic impacts. Cancer survivors treated with conventional non-HCT therapy are known to be at a higher risk of unemployment or not returning to work after completion of therapy compared with the control population. However,
-
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-09-19 Ginna Granroth, Nandita Khera, Cecilia Arana Yi
-
Pediatric Germline Predisposition to Myeloid Neoplasms Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-09-19 Christineil Thompson, Sydney Ariagno, Mira A. Kohorst
-
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-09-01 Barbara Mora, Francesco Passamonti
Purpose of Review Philadelphia-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), prefibrotic (pre-), and overt-primary myelofibrosis (primary MF, PMF). PV and ET could evolve into secondary MF (SMF), whose early diagnosis relies on monitoring signs of possible progression. All MPNs have a risk of blast phase (BP), that is associated with a
-
Value in Myeloma Care: Myth or Reality Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-08-30 Evguenia Ouchveridze, Katherine Berger, Ghulam Rehman Mohyuddin
-
Bispecific Antibodies for the Treatment of Multiple Myeloma Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-08-27 Scott R. Goldsmith, Shawn Streeter, Fahrettin Covut
-
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-08-20 Anmol Baranwal, Christopher N. Hahn, Mithun Vinod Shah, Devendra K. Hiwase
-
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-08-19 Julian A. Waksal, John Mascarenhas
-
Precision Medicine in Myeloid Malignancies: Hype or Hope? Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-08-16 Shristi Upadhyay Banskota, Nabin Khanal, Rosalyn I. Marar, Prajwal Dhakal, Vijaya Raj Bhatt
-
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia Curr. Hematol. Malig. Rep. (IF 2.9) Pub Date : 2022-08-06 Ivan Krecak, Marko Lucijanic, Srdan Verstovsek
Purpose of Review Estimating and modifying thrombotic risk is currently the mainstay of care for patients with polycythemia vera (PV) and essential thrombocythemia (ET). In recent years, however, increased attention has shifted towards quality of life and disease modification. In this review, we discuss recent advances in risk stratification, present updated results for ruxolitinib and interferon randomized